文献速递眼整形与眼眶

预测羟基磷灰石眶内植入物暴露风险的列线图

Nomogram for predicting implant exposure risk following enucleation or evisceration with vicryl-meshed hydroxyapatite implants.
PubMed 文献 · Br J Ophthalmol · 2026-09-22

这项单中心回顾性研究纳入336例接受Vicryl网包裹羟基磷灰石眶内植入物的患者,通过多因素logistic回归识别植入物暴露的独立危险因素并构建列线图。列线图在训练集与验证集中AUC均为0.725,校准良好,决策曲线分析支持其临床实用性。

要点

  • 既往眼外伤、糖尿病、自身免疫病、放化疗、激素治疗及既往眼部手术是植入物暴露的独立危险因素。
  • 列线图区分度中等(AUC 0.725),校准良好,决策曲线分析提示有临床净获益。
  • 研究为单中心,结论仅适用于Vicryl网包裹的羟基磷灰石植入物,需外部验证。

核心结论

  • 列线图可识别Vicryl网包裹羟基磷灰石植入术后植入物暴露高风险患者,辅助个体化预防策略。

研究设计与样本

  • 德国科隆大学医院单中心回顾性研究,纳入336例接受初次Vicryl网包裹羟基磷灰石眶内植入物的患者。
  • 采用单因素及多因素logistic回归筛选植入物暴露的独立危险因素,构建列线图并用AUC、校准曲线和决策曲线分析评价。

主要发现

  • 植入物暴露的独立危险因素包括既往眼外伤(OR 2.08;95%CI 1.01至4.31;p=0.048)。
  • 糖尿病(OR 4.17;95%CI 1.81至9.63;p<0.001)和自身免疫病(OR 4.69;95%CI 1.15至19.09;p=0.031)为独立危险因素。
  • 化疗或放疗(OR 4.25;95%CI 1.09至16.58;p=0.037)、激素治疗(OR 2.35;95%CI 1.04至5.30;p=0.039)及既往眼部手术(OR 2.65;95%CI 1.33至5.27;p=0.005)亦为独立危险因素。
  • 列线图在训练集和验证集中的AUC均为0.725,校准曲线良好,决策曲线分析支持其临床实用性。

关键数值与推荐

  • 列线图区分度AUC为0.725(训练集与验证集相同),校准良好,决策曲线分析显示潜在临床效用。

临床怎么用

  • 可用于术前识别Vicryl网包裹羟基磷灰石植入术后植入物暴露高风险患者,指导个体化预防策略。

局限性

  • 单中心研究,适用性仅限于该植入物类型及包裹技术,需在其他中心及人群中外部验证以确认泛化性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To develop and validate a nomogram predicting the risk of implant exposure in patients receiving vicryl-meshed hydroxyapatite (HA) orbital implants following enucleation or evisceration. METHODS: This is a retrospective study at the University Hospital of Cologne, which included 336 patients with primary vicryl-meshed HA implants. Univariate and multivariate logistic regression analyses identified independent risk factors for implant exposure. A nomogram was constructed, and its performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves and decision curve analysis (DCA). RESULTS: Independent risk factors for implant exposure included previous ocular trauma (OR 2.08; 95% CI 1.01 to 4.31; p=0.048), diabetes mellitus (OR 4.17; 95% CI 1.81 to 9.63; p<0.001), autoimmune disease (OR 4.69; 95% CI 1.15 to 19.09; p=0.031), chemotherapy or radiotherapy (OR 4.25; 95% CI 1.09 to 16.58; p=0.037), hormone therapy (OR 2.35; 95% CI 1.04 to 5.30; p=0.039) and previous ocular surgery (OR 2.65; 95% CI 1.33 to 5.27; p=0.005). The nomogram demonstrated moderate discriminative ability (AUC 0.725 for both training and validation sets) and good calibration, with potential clinical utility supported by DCA. CONCLUSION: This nomogram provides a practical tool for identifying patients at higher risk of exposure following vicryl-meshed HA implantation and may inform individualised preventive strategies. As this is a single-centre study, its applicability is currently limited to this implant type and wrapping technique, and external validation in other centres and populations is needed to confirm its generalisability.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wang M, Heindl LM, Salim ORS, et al. Nomogram for predicting implant exposure risk following enucleation or evisceration with vicryl-meshed hydroxyapatite implants. Br J Ophthalmol. 2026. PMID: 41946558. doi:10.1136/bjo-2025-328883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。